Clinical Trial Detail

NCT ID NCT04160195
Title T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

CLL/SLL

B-cell lymphoma

primary mediastinal B-cell lymphoma

gray zone lymphoma

mantle cell lymphoma

Burkitt lymphoma

diffuse large B-cell lymphoma

Hodgkin's lymphoma

Therapies

Cyclophosphamide + Fludarabine

Anti-CD19-CD20 CAR T cells

Age Groups:

No variant requirements are available.